SUSMED,Inc. (4263) AI Stock Analysis

• Market Cap: ¥15.38B
• Dividend Yield: N/A
• Average Volume (3M): 144.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: 39.30%
• EPS Growth: 32.06%
• Country: JP
• Employees: 39
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -7.17
• Shares Outstanding: 16,860,400
• 10 Day Avg. Volume: 108,050
• 30 Day Avg. Volume: 144,173
• PEG Ratio: 2.02
• Price to Book (P/B): 2.35
• Price to Sales (P/S): 22.16
• P/FCF Ratio: -23.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 2,608.56
• Revenue Forecast (FY): ¥217.12B

• Rating: 45 Neutral
• Price Target: ―

SUSMED, Inc. faces substantial challenges in profitability and cash flow, significantly impacting its financial performance. The technical indicators suggest a mixed market sentiment with a potential for short-term correction. The valuation is unattractive due to ongoing losses and no dividend yield. These factors result in a below-average stock score, highlighting the need for operational improvements and revenue growth to enhance investor appeal.

SUSMED,Inc. Business Overview & Revenue Model

Company Description

SUSMED, Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. The company also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, it offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.

How the Company Makes Money

SUSMED, Inc. generates revenue primarily through the development and commercialization of its digital therapeutic applications. The company partners with healthcare providers, insurance companies, and other stakeholders in the medical field to distribute its products. Revenue streams include licensing fees for the use of its technology, subscription fees from users, and collaborations with pharmaceutical companies for research and development of new therapeutic solutions. Additionally, SUSMED may engage in partnerships to expand its reach and integrate its offerings with existing healthcare systems, thereby enhancing its market presence and revenue potential.

SUSMED,Inc. Financial Statement Overview

Summary

SUSMED, Inc. is facing significant challenges in profitability and cash flow generation. While the company benefits from a strong equity base and no debt, persistent net losses and negative operating cash flow hinder financial stability. The strategic focus should be on improving operational efficiencies and revenue growth to enhance financial performance.

Income Statement

The company shows a negative revenue growth trend with decreasing revenue from 2023 to TTM. Gross profit margin remains relatively high, but significant net losses persist, implying poor cost management or excessive expenses. Both EBIT and EBITDA margins are negative, indicating operational inefficiency and a struggle to cover operational costs.

Balance Sheet

The company maintains a robust equity position with a debt-free balance sheet, reflected in a solid equity ratio. However, the substantial losses negatively impact ROE. The high cash reserves provide a buffer against operational losses but do not compensate for the lack of profitability.

Cash Flow

Cash flow from operations remains negative, with no free cash flow growth. The lack of positive operating cash flow relative to net income indicates insufficient cash generation from core operations. The company's reliance on financing activities to sustain cash reserves is a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	452.45M	462.99M	342.58M	530.65M	316.87M	115.49M
Gross Profit	441.66M	450.72M	330.85M	522.67M	306.50M	105.73M
EBITDA	-275.84M	-289.22M	-358.99M	-43.99M	-228.00M	-333.31M
Net Income	-284.47M	-298.40M	-357.42M	-50.75M	-233.48M	-277.55M
Balance Sheet
Total Assets	4.66B	4.50B	4.93B	5.10B	4.94B	1.67B
Cash, Cash Equivalents and Short-Term Investments	4.54B	4.40B	4.85B	5.05B	4.90B	1.63B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	142.94M	132.33M	327.79M	230.33M	93.34M	97.20M
Stockholders Equity	4.51B	4.37B	4.60B	4.87B	4.85B	1.58B
Cash Flow
Free Cash Flow	0.00	-436.79M	-240.04M	82.40M	-177.90M	-239.49M
Operating Cash Flow	0.00	-432.48M	-230.76M	100.59M	-165.28M	-235.09M
Investing Cash Flow	0.00	-19.97M	-8.53M	-18.19M	-20.36M	-4.40M
Financing Cash Flow	0.00	3.67M	37.37M	62.36M	3.46B	1.50B

SUSMED,Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 889.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Positive. The current price of 889 is below the 20-day moving average (MA) of 913.45, below the 50-day MA of 891.20, and above the 200-day MA of 698.64, indicating a bullish trend. The MACD of 9.61 indicates Positive momentum. The RSI at 52.55 is Neutral, neither overbought nor oversold. The STOCH value of 71.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4263.

SUSMED,Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4320	74 Outperform	¥17.60B	16.72	―	2.19%	8.77%	1106.00%
9218	73 Outperform	¥8.78B	26.60	―	―	64.32%	289.65%
3939	67 Neutral	¥22.76B	22.38	―	1.57%	13.39%	12.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2934	50 Neutral	¥9.68B	120.89	―	―	11.40%	―
4263	45 Neutral	¥15.38B	―	―	―	39.30%	32.06%
3902	43 Neutral	¥17.43B	-23.82	―	1.46%	-0.58%	-260.22%